Date: 2017-07-21
Type of information: Development agreement
Compound: ALG.APV-527
Company: Alligator Bioscience (Sweden) Aptevo Therapeutics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism:
- bispecific antibody/immune checkpoint inhibitor/immunotherapy product. ALG.APV-527 is a bispecific agonistic antibody targeting 4-1BB (CD137), a member of the TNFR superfamily of co-stimulatory receptors found on activated T cells, and an undisclosed tumor-associated antigen (TAA) widely overexpressed in a number of different types of cancer.
- The co-stimulatory receptor 4-1BB is known to play an important role in modulating and augmenting the immune response to cancer by promoting the activation, expansion and enhanced effector function of tumor-specific T cells. It is, therefore, an especially promising target for new immunotherapeutic approaches for cancer treatment. If successfully developed, this new bispecific antibody candidate could have utility in the potential treatment of a broad spectrum of cancers including breast, cervical, non-small-cell-lung, prostate, renal, gastric, colorectal and bladder cancers. While this tumor antigen is widely expressed in multiple types of solid tumors, it shows limited expression on normal tissues, suggesting the potential for tumor-directed immunotherapy with improved efficacy and fewer side effects.
- It was co-developed with Aptevo Therapeutics. It was generated by proprietary binding elements obtained from Alligator’s ALLIGATOR-GOLD® antibody library, which were produced as a bispecific compound using Aptevo’s bispecific technology platform. ALG.APV-527 is based on Alligator’s first generation bispecific antibody, ATOR-1016.
Disease:
Details:
- • On July 21, 2017, Aptevo Therapeutics and Alligator Bioscience announced that they have entered into an agreement to co-develop a novel immunotherapy bispecific antibody candidate, ALG.APV-527, based on Alligator’s first generation bispecific antibody, ATOR-1016. Initiation of cell line development for the manufacturing of clinical material is expected to begin shortly.
Under the terms of the agreement, the parties will jointly own and share equally in the development costs associated with advancing this candidate through to the end of Phase 2 clinical development. At that time, the parties may opt to out-license the candidate or continue further development separately or in partnership. In addition, the agreement provides an option for the companies to develop a second bispecific antibody candidate based on this novel mechanism of action, which would also be jointly owned and funded by Aptevo and Alligator.
Financial terms:
Latest news:
- • On August 17, 2017, Aptevo Therapeutics and Alligator Bioscience announced that the companies have initiated CMC activities for the manufacturing of clinical material in preparation for a future investigational new drug (IND) submission for the bispecific immuno-oncology antibody ALG.APV-527.
Is general: Yes
